Revenue, 2025

USD 611.1 Million

Forecast, 2035

USD 899.37 Million

CAGR, 2026-2035

3.94%

Report Coverage

Global

Adapalene Market Trends for 2026

The global adapalene market size was estimated at USD 611.1 million in 2025 and is predicted to increase from USD 635.18 million in 2026 to approximately USD 899.37 million by 2035, expanding at a CAGR of 3.94% from 2026 to 2035.

The adapalene market is growing because adapalene encourages collagen manufacturing, supporting to improve skin texture and reduce signs of aging. It works moderately by clearing skin pores.

Key Takeaways

• The adapalene market will likely exceed USD 635.18 million by 2026.
• Valuation is projected to hit USD 899.37 million by 2035.
• Estimated to grow at a CAGR of 3.94% starting from 2026 to 2035.
• North America dominated the adapalene market in 2025, with 38% revenue share.
• Asia Pacific is seen to grow at a CAGR of 6.0% during the forecast period, and it also held a considerable share of 31% of the market in 2025.
• By product type, the gel segment held the largest market share of 74% in 2025.
• By product type, the lotion/others segment held 8% of the total market share in 2025, and is expected to grow notably during the forecast period.
• By formulation type, the prescription-based segment held the largest market share of 59% in 2025.
• By formulation type, the over-the-counter (OTC) segment held the second-largest market share of 41% in 2025, and is expected to grow at a notable CAGR during the forecast period.
• By application, the acne treatment segment held the largest revenue share of approximately 65% of the market in 2025.
• By application, the other dermatological conditions segment held a notable share of approximately 15% in 2025 and is estimated to grow at a notable CAGR during the forecast period.
• By distribution channel, the hospital pharmacies & clinics segment dominated the adapalene market with approximately 46% revenue share in 2025.
• By distribution channel, the online pharmacies segment held a notable market share of approximately 19% in 2025, and is estimated to be notably growing during the forecast period.

Market Overview: What is Adapalene?

The adapalene market is growing, as it is a topical retinoid that is FDA-approved for managing acne vulgaris. Adapalene is obtainable only with a physician's prescription. This product is obtainable in the following dosage forms: solution, cream, gel/jelly, lotion, and swab. It reduces acne by averting pore blockage and promoting skin cell turnover. Adapalene is a third-generation up-to-date retinoid used for the treatment of acne vulgaris. Adapalene has similar efficacy but superior safety. Adapalene is indicated for the topical management of acne vulgaris in patients aged 12 and over.

How is AI governing the Adapalene Market?

AI-driven technology plays a significant role in evolving technologies, which is strategically important in shaping the adapalene. Adapalene is an extremely efficient skincare ingredient with multiple functions. Its significant function lies in modifying the skin cell shedding technology. AI-based technology is applied to develop and optimize adapalene-driven solid lipid nanoparticles (SLNs) or nanocarriers, which enhance the medicine stability, skin penetration, and localization in the epidermal layer while lowering systemic exposure. The application of artificial intelligence (AI) and machine learning (ML) in medical research is altering the way healthcare research is conducted. AI-based cosmetogenomics is progressing dermatology into an analytical and personalized era.

Future Outlook & Trends in the Adapalene Market

• Combination Therapies for Enhanced Efficacy: Combination therapies show a promising border in cancer management, addressing the significant requirement to improve effectiveness while minimizing resistance.  These therapies that involve a repurposed therapeutic agent demonstrated enhanced efficiency and efficacy.
• Drug Repurposing: Drug repurposing provides advantages in comparison with traditional drug advancement technology, lowering time and risk. It has become a promising strategy in oncology, offering faster, safer, and more affordable therapeutic advancement by leveraging present drugs with established safety profiles.
• Technological Formulation Improvements: AI-based formulation quickens development as compared with conventional delivery instruments, while advanced production and regulatory approaches ensure scalability and compliance.

Quick Facts Table

Segmentation Analysis

By Product Type Insights

The Gel Segment Led the Adapalene Market in 2025

Explanation

• Gel – Thick, water-based formulations used for skincare and medicinal purposes, accounting for 74% share due to their effectiveness and popularity in various treatments.
• Cream – Semi-solid emulsions for moisturizing and treatment, holding 18% share with steady demand in both cosmetic and therapeutic applications.
• Lotion/Others – Lighter formulations like lotions and alternative products, representing 8% share with niche applications in skin care and hydration.

The gel segment contributed the largest market share of 74% in 2025, as this skin gel treats mild to moderate acne. Apply this gel to the affected skin as directed. The gel is typically applied once daily to the affected areas of the skin. It acts as a significant comedolytic, clearing existing blackheads and whiteheads while stopping new acne from forming by keeping pores clean. It reduces the redness, swelling, and inflammation related to acne pustules and papules.

The cream segment held the second-largest share of 18% of the market in 2025, as this cream regularizes the differentiation of follicular epithelial cells to avoid microcomedone formation. It works by avoiding the accumulation of sebum, which unblocks the pores.

Whereas the lotion/others segment held a notable share of 8% of the market in 2025, as it efficiently prevents acne by normalizing skin cell turnover, clearing pores, and offering anti-inflammatory advantages, often resulting in smoother, clearer skin within 4-8 weeks. Adapalene-based lotion is a form of vitamin A that manages acne.

By Formulation Type Insights

The Prescription-based Segment Led the Adapalene Market in 2025

Explanation

• Prescription-based – Medications requiring a doctor's prescription, accounting for 59% share due to their use in treating more serious or specialized health conditions.
• Over-the-Counter (OTC) – Medications available without a prescription, holding 41% share with growing demand for self-care and non-prescription treatments.

The prescription-based segment contributed the largest market share 59% in 2025, as it has significant benefits such as providing efficient treatment, disease prevention, enhanced quality of life, and targeted care that adapts to patient requirements. The precision of prescription medications enables healthcare providers to address challenging conditions that need particular therapeutic interventions.

Whereas the over-the-counter (OTC) segment held the second largest share of 41% of the market in 2025, as application of OTC drugs is related to major benefits, including limiting doctor visits and being more affordable compared with prescription drugs. OTC drugs enhance access, convenience, service, health results, and individual satisfaction.

By Application Insights

The Acne Treatment Segment held the largest share in the market in 2025

Explanation

• Acne Treatment – Products for treating acne, accounting for 65% share due to the high prevalence of acne and demand for effective skincare solutions.
• Keratosis Pilaris / Callus / Others – Products for conditions like keratosis pilaris and calluses, holding 20% share with targeted use for specific skin conditions.
• Other Dermatological Conditions – Treatments for various other skin issues, representing 15% share with niche applications in dermatology.

The acne treatment segment contributed the largest market share of approximately 65% in 2025, as it reduced mild post-acne marks and scars because of its capability to promote novel skin cell growth. Adapalene is applicable to treat acne. It functions partly by keeping skin pores strong. Adapalene is obtainable only with a physician’s prescription. Adapalene is pointedly less irritating than first-generation retinoids such as tretinoin.

The keratosis pilaris/callus/other segment held approximately 20% share of the adapalene market in 2025, as adapalene is extremely efficient in managing keratosis pilaris (KP) because of its unique capability to modulate keratinocyte differentiation and lower keratin accumulation. It is used off-label to manage keratosis pilaris as well as other skin conditions.

Whereas the other dermatological conditions segment held a notable share of approximately 15% in the market in 2025, as adapalene enables efficient regulation of keratinocyte differentiation and inflammatory technology while reducing skin irritation. Adapalene is more UV-stable than other prescription retinoids; it is less likely to break down when exposed to sunlight.

By Distribution Channel Insights

The Hospital Pharmacies & Clinics Segment held the Largest Share of the Market in 2025

Explanation

• Hospital Pharmacies & Clinics – Pharmacies located within hospitals and clinics, accounting for 46% share due to their direct access to healthcare providers and patients.
• Retail Pharmacies – Traditional brick-and-mortar pharmacies, holding 35% share with widespread availability and convenience for consumers.
• Online Pharmacies – E-commerce platforms for purchasing medications, representing 19% share with growing adoption driven by convenience and increased online shopping.

The hospital pharmacies & clinics segment contributed the largest market share of approximately 46% in 2025, as these services empower hospitals to raise the quality of patient care, increasing clinical abilities, and drive stronger partnerships among healthcare professionals. Pharmacists work directly with physicians and nurses.

The retail pharmacies segment held the second largest share of approximately 35% of the adapalene market in 2025, as retail pharmacies are a significant part of medical care systems and, in major countries, are accountable for dispensing a massive proportion of health products. Retail pharmacies play an important role in medical care by offering convenient access to medicines and a broad range of products.

Whereas the online pharmacies segment held a notable share of approximately 19% in the market in 2025, as these types of pharmacies often provide competitive pricing, discounts, and generic substitutes, leading to potential expense savings for patients. An online pharmacy is a simple and convenient way to purchase medicines. It is specifically advantageous for patients who live far away from medical stores.

Regional Insights

Why North America Dominated the Market in 2025?

In 2025, North America dominated the adapalene market, with 38% revenue share, because of increasing pubertal age, seborrhoea, mental stress, premenstrual phase, and sweet and oily foods were recognized as challenging factors for moderate to severe acne, which drives the demand for adapalene-based services.  Advancements in dermatology, driven by progress in technology, therapeutics, and a deeper understanding of the societal requirements of various populations, drive the growth of the market.

U.S. Market Trends

In the U.S., Acne vulgaris is a common inflammatory skin challenge related to psychosocial distress and lessened quality of life. The U.S. is a significant importer of Indian-produced Adapalene API, allowing US manufacturers to manufacture high volumes of affordable, FDA-driven generic products.

Asia Pacific: Increasing Healthcare Awareness

Asia Pacific is seen to grow at a CAGR of 6.0% during the forecast period. It also held a considerable share of 31% of the adapalene market in 2025, as growing healthcare awareness leading to enlarged health demand has, directly and indirectly, hassled the ruling governments in the region to spend in the health sector. Increasing burden of acne vulgaris in adolescents and young adults aged 10-24 years. 92% of the Asia Pacific's population, about 4 billion people, are exposed to levels of air pollution that pose a significant challenge to their health, leading to an increase in acne cases in multiple age groups, which drives the growth of the market.

India Market Trends

The Indian pharma sector advantages from comparatively reduced manufacturing expenses, skilled labour, and economies of scale. Major production organizations offer a wide variety of healthcare products, including manufacturing, packing, labelling, and even delivery of the products.  India is a consistent producer of bulk drugs and finished healthcare products because of its large-scale production capacity.

Supply Chain Analysis

R&D:

• Research and development (R&D) for adapalene involves advanced formulation technology, characterization, stability testing, and in vitro/in vivo effectiveness research.
• Key Players: Sun Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Ltd.

Manufacturing Processes:

• Manufacturing processes in adapalene involve the biochemical synthesis of the active pharmaceutical ingredient (API) and the pharmaceutical formulation into topical products such as gels or creams.
• Key Players: Perrigo Company plc and Glenmark Pharmaceuticals Ltd.

Patient Services:

• Patient services, including adapalene, primarily focus on the diagnosis, prescription, and long-term management of acne vulgaris and different dermatological conditions.
• Key Players: Galderma S.A. and Teva Pharmaceutical Industries Ltd

Latest Updates of Key Players in the Adapalene Market

SWOT Analysis

Strengths

• Adapalene helps in pigment disorders like melasma and dark spots resulting from acne and sun exposure. It is applicable to manage alopecia areata.
• Adapalene is a significant yet gentle retinoid that benefits acne-prone, hyperpigmented, and aging skin. Its capability to moderate skin cell growth, lower inflammation, and prevent pore clogging makes it a significant choice for both medical and cosmetic skincare rights.

Weakness

• Adapalene side effects are generally skin-related, like dryness and redness, where the invention is applied.

Opportunities

• Novel microspongeal gel solutions are being applied to improve effectiveness in lowering comedonal lesions while further reducing potential skin irritation.
• Adapalene-loaded niosomal gels have been industrialized to boost skin retention and lower irritation, offering a friendlier substitute to conventional creams. 

Threat

• Adverse responses of adapalene involve irritation, photosensitivity, redness, dryness, itching, and burning.

Recent Developments in the Adapalene Market

• In August 2025, Bausch Health, Canada Inc., part of Bausch Health Companies Inc., a worldwide, diversified pharmaceutical organization, announced that PrCABTREO gel 1.2% w/w, 0.15% w/w, and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to recipients of the public drug plans of Quebec and Saskatchewan
• In September 2025,  Sol-Gel Technologies, Ltd., a dermatology organization, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 for Gorlin syndrome, a Phase-1b, double-blinded clinical trial of SGT-210 on Darier disease patients, and with two approved large-category dermatology products, TWYNEO and EPSOLAY, announced that Health Canada issued a Notice of Compliance (NOC) for EPSOLAY for the treatment of inflammatory lesions of rosacea in adults.
• In April 2025, Sol-Gel Technologies, Ltd., a clinical-stage dermatology organization, announced it had entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO.

Segments Covered in the Report

By Product Type

• Gel
• Cream
• Lotion/Others

By Formulation Type

• Over-the-Counter (OTC)
• Prescription-based

By Concentration

• 0.1% Adapalene
• 0.3% Adapalene
• Combination formulations

By Application

• Acne Treatment
• Keratosis Pilaris / Callus / Others
• Other dermatological conditions

By Distribution Channel

• Hospital Pharmacies & Clinics
• Retail Pharmacies
• Online Pharmacies

By End User

• Dermatology Clinics
• Hospitals
• Homecare

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA